Board summary
Key figures
34,855
Registered population
60.0% aged 18–64
17.6%
Aged 65+
ICB 14.9% · England 17.9%
44.0%
In IMD quintile 1
ICB 40.7% · England 21.0%
~13,969
Core20 residents (est.)
Resident basis; registered basis ~15,483 · see page 3
5,995
Hypertension register
+7.22% in 3 yrs · England +5.60%
444
SMI register
14.3% of Rochdale (LAD)'s
1,186
COPD register
Reviews -5.57% in 3 yrs
Forecast to 2030
7,176
Hypertension patients, 2030
+1,181 on today
70.7%
QRISK ≥20% on statins, 2030
+2.86pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD review rate trails England over three years.
COPD annual reviews changed by -5.6% from 2023 to 2025 (England +2.8%) while register prevalence grew +18.4%, which may reflect review capacity pressures.
SMI physical checks and LD register lag comparators.
SMI blood pressure checks reach 78.8% (England 83.4%) and BMI checks 75.5% (England 82.1%), alongside a -41.2% three-year learning disability prevalence change.
Younger women's cervical screening coverage exceeds all comparators.
Cervical screening coverage at ages 25-49 reaches 73.8%, standing 6.9 pp above England (66.8%) and 5.0 pp above Rochdale (68.8%).
Population, age and ethnicity
Older adults at 17.6% exceed borough and ICB rates alongside a 22.5% youth share
Across five practices totaling 34,855 registered patients, children aged 0–17 comprise 22.5% (7,838 patients), below Rochdale (23.5%) but above the ICB (21.8%) and England (19.6%). Conversely, 17.6% are aged 65+ (6,123 patients), exceeding Rochdale (14.7%) and the ICB (14.9%) while below England (17.9%). Working-age adults account for 60.0% (20,894 patients). Recorded Gypsy or Irish Traveller residents represent 0.1% (Rochdale 0.1%, ICB 0.1%, England 0.1%) and Roma 0.1% (Rochdale 0.1%, ICB 0.1%, England 0.2%). Projected list growth is 1.9% to 2030 via unverified methodology; observation periods were not supplied.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 44.0% and varies by 30.8 percentage points across practices
Across the PCN, 44.0% of registered patients live in Core20 areas, above England (21.0%) and the ICB (40.7%), but below Rochdale (48.0%). A 0.42 pp reconciliation gap separates this from the 44.4% practice-weighted rate and 13,969 resident estimate. Concentration spans 30.8 pp, from 27.2% at Hopwood Medical Centre to 58.0% at Heywood Health. Targeting requires separating share from volume: Heywood Health leads on both (58.0%; 4,871 patients), but Longford Street Medical Centre holds the second largest caseload (3,645 patients) despite a lower share (43.8%).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
444
SMI register
1.28% recorded prevalence
235
Learning disability register
0.68% recorded prevalence
7
Care homes, 252 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
The severe mental illness register records 444 patients (1.3%; Rochdale 1.2%, ICB 1.1%, England 1.0%), while learning disability prevalence is 0.7% (235 patients; Rochdale 0.7%, ICB 0.6%, England 0.6%). The catchment has 7 care homes with 252 beds, though occupancy was not captured. Above-average register prevalence and care home bed capacity require coordinated proactive health reviews.
Severe mental illness: physical health checks
SMI prevalence is 1.3% (444 patients). Blood pressure checks reach 78.8% (England 83.4%), with BMI checks at 75.5% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,995
Hypertension register
+7.22%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
−1.15pp
BP control, under 80
≤140/90 · −0.96pp aged 80+
+1,181
More patients by 2030
Forecast 7,176 (19.92%)
Hypertension case-finding and control
Heywood PCN records 5,995 patients on its hypertension register, representing 17.3% prevalence (England 15.2%, Rochdale 15.6%, NHS Greater Manchester ICB 14.4%). Recent blood pressure checks reach 91.4% (England 90.0%, Rochdale 89.5%, ICB 90.3%), and control is 70.7% (England 70.3%, Rochdale 70.5%, ICB 71.4%). However, patients treated to target fell 1.9% over three years (2023 to 2025; England +3.6%, Rochdale +2.8%, ICB +3.5%), and control in under-80s fell 1.7% (England +3.2%, Rochdale +3.1%, ICB +3.6%). Slower progress could reflect review capacity pressures as registers grew (+7.2% vs England +5.6%), unverified locally. Denominators include personalised care adjustments. Three-year declines in blood pressure control indicate treated patients risk suboptimal outcomes.
Lipids and statins
Statin coverage in diabetes without CVD is 71.3% (England 73.2%, Rochdale 76.6%, NHS Greater Manchester ICB 75.7%) and with CVD is 82.3% (England 84.4%, Rochdale 86.5%, ICB 85.8%). QRISK ≥ 20% therapy reaches 64.6% (England 63.6%, Rochdale 68.3%, ICB 67.0%). Denominators include personalised care adjustments. Lower statin uptake in diabetes trails all comparators.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 67,556 | £2.40 | £1.94 | £1.86 | £162,134 |
| Cardiovascular (all), 2025 | 87,858 | £2.71 | £3.15 | £3.33 | £238,095 |
In 2026, the PCN prescribed 67,556 lipid-regulating items at £2.40 per item, above England (£1.86), Rochdale (£2.08) and NHS Greater Manchester ICB (£1.94), spending £36,480 more than at England's unit cost across 67,556 items. Unit cost reflects drug mix, not efficiency. Higher unit costs indicate an opportunity to review lipid formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.10%
Asthma prevalence, PCN 3-yr % change
Patients with Asthma: review in the last 12 months (denominator incl. PCAs) is 67.2% at PCN level, above Rochdale (LAD) (66.2%), NHS Greater Manchester Integrated Care Board (66.2%) and England (65.7%). Denominators include personalised care adjustments. Respiratory review coverage is above comparators; sustaining review delivery remains the priority.
Cancer register and children's immunisation
Cancer prevalence is 4.1% (1,425 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 12 months is 88.0%, below the 95.0% target by 7 pp. At age 5, MMR dose 1 reaches 92.7% and dose 2 is 86.5% (below the 95.0% target by 8.5 pp), showing a 6.2 pp dose difference. The 4-in-1 pre-school booster reaches 83.3%, below the 95.0% target by 11.7 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage (6,491 of 11,679) across NHS Greater Manchester ICB were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staged cancers represented 70.8% of 16,492 registered ICB cases. This ICB data reflects wider system pathways rather than PCN performance. Heywood PCN's cancer register reached 1,425 patients (4.1% prevalence) after +11.9% three-year growth (England +9.0%). Cervical screening reached 73.8% (England 66.8%), while breast screening coverage grew +4.7% to 69.5%, trailing England (+8.4%). Slower breast screening expansion may delay early detection, warranting targeted practice recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day cancer standard, 6.4 pp below the 85.0% target, but above Bolton NHS Foundation Trust (69.7%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%), and England (71.2%). On 28-day faster diagnosis, the trust reached 75.2% (meeting the 75.0% standard; ICB 79.5%, England 79.3%). In diagnostics, 31.5% of echocardiography patients waited 6+ weeks (England 28.5%), while MRI was 5.1% (England 21.4%). Provider diagnostic delays could affect timely oncology treatment pathways.
| Pathways within standard (%) | Northern Care Alliance | Bolton | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.50 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 69.66 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Bolton | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 2.05 | 11.68 | 21.40 |
| CT | 4.10 | 19.40 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 3.48 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.33 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 2.06 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 15.78 | 8.98 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In Jun 2026, 40.9% of community service contacts for Rochdale residents (24,650 of 60,250) were with adults aged 65 and over. These figures reflect borough-level resident activity rather than PCN-level provision. Heywood PCN has 6,123 registered patients aged 65+ (17.6% of the list). Aligning primary anticipatory care with community teams is essential to support the PCN's older population.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Birtle View | 96 | 55.8 | 81.3% | 83.1% | 91.8% |
| Hopwood | 85 | 27.2 | 81.3% | 75.7% | 87.7% |
| Heady Hill Surgery | 99 | 46.0 | 79.0% | 78.1% | 81.7% |
| Longford Street | 123 | 43.8 | 66.8% | 63.4% | 77.2% |
| Heywood Health | 100 | 58.0 | 38.6% | 72.3% | 66.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 measures trail England's three-year change, led by learning disability contraction
Across 25 compared measures, 19 trail England's three-year change from 2023 to 2025. The widest relative lags occurred in learning disability QOF prevalence at -41.2% (England +5.4%), heart failure reviews at +0.3% (England +8.7%), COPD reviews at -5.6% (England +2.8%), and asthma reviews at -2.2% (England +4.4%). Conversely, smoking cessation support changed by +2.9 pp (England +0.1 pp), and statins for diabetes without cardiovascular disease changed by +4.9% (England +2.1%). Clinical and operational drivers behind trailing review trends remain unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
COPD reviews
Asthma reviews
Hypertension treated to target
Smoking support (SMI)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (252 beds) | n/a | Schools (catchment) | 33 | n/a |
| Children's centres | 3 | 17 | Places of worship | 21 | 116 |
| Libraries | 2 | 12 | Primary schools (LA maintained) | 6 | 38 |
| Primary academies | 4 | 26 | Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma review coverage is 67.2% of 2,414 patients (791 unreviewed; 3-year change -2.2% over 2023 to 2025 vs England +4.4%); COPD review 3-year change is -5.6% (England +2.8%). For discussion: standardise annual respiratory review templates, align inhaler prescribing checks with proactive recall, and offer flexible clinic slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pharmacist-led hypertension and statin review
Hypertension control (70.7%) changed by -1.9% over 2023 to 2025 (England +3.6%; under-80s -1.7% vs +3.2%); diabetes statin coverage is 71.3% (England 73.2%). For discussion: run pharmacist-led titration recalls for patients above blood pressure thresholds and review statin initiation in eligible diabetes cohorts. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
SMI checks and LD register audit
SMI blood pressure checks are 78.8% (England 83.4%) and BMI checks 75.5% (England 82.1%); the learning disability register (235 patients, 0.7%) fell 41.2% over 2023 to 2025 (England +5.4%). For discussion: combine SMI physical check components into single outreach appointments and validate learning disability coding against historical practice lists. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dual age cohort capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted SMI physical checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Breast screening recall outreach (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD: QOF prevalence | Core20PLUS5 respiratory | PCN |
| Option 2 · Pharmacist-led hypertension and statin review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · SMI checks and LD register audit (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
